<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/new-data-at-ddw-2026-show-tissuecypher-testing-improves-risk-stratification-and-drives-risk-aligned-management-in-barretts-esophagus-302760759.html">New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett&#39;s Esophagus</a>
    </div>

      <div class="me-0 me-md-5">
        Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study showing changes in surveillance intervals in more than half of patients compared with recommendations guided by traditional histopathology, supporting more personalized, risk-aligned patient ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/castle-biosciences-to-present-new-data-demonstrating-decisiondx-melanomas-ability-to-identify-patients-with-greater-risk-of-recurrence-and-poor-outcomes-within-early-stage-melanoma-at-eado-and-acms-302747617.html">Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma&#39;s Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS</a>
    </div>

      <div class="me-0 me-md-5">
        Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk insights to guide more precise, risk-aligned clinical management FRIENDSWOOD, Texas, April 21, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innov...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/castle-biosciences-to-release-first-quarter-2026-financial-results-and-host-webcast-on-wednesday-may-6-2026-302741021.html">Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the close of market on Wednesday, May 6, 2026. Company management will host a webcast to discuss its financial results ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/castle-biosciences-earns-2026-usa-today-top-workplaces-award-for-fifth-consecutive-year-302738633.html">Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year</a>
    </div>

      <div class="me-0 me-md-5">
        FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. The national award program by Energage and USA TODAY celebrates organizations with 150 or more employees that have ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4887193-castle-biosciences-buying-the-remaining-decisiondx-melanoma-upside">Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside</a>
    </div>

      <div class="me-0 me-md-5">
        Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/castle-biosciences-decisiondx-melanoma-test-significantly-improves-risk-prediction-within-ajcc-stages-to-support-personalized-risk-aligned-management-of-cutaneous-melanoma-data-to-be-presented-at-aad-2026-302725368.html">Castle Biosciences&#39; DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC) stages and T categories, identifying patients whose mortality risk is substantially higher or lower than staging alone would predict FRIENDSWOOD, Texas, March 27, 2026 /PRNewswire...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4885127-castle-biosciences-inc-cstl-discusses-clinical-utility-and-evidence-supporting-decisiondx">Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Castle-Biosciences-Inc-US14843C1053">Castle Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/13/3255641/0/en/Prospective-Multi-center-Study-Published-in-Future-Oncology-Demonstrates-DecisionDx-Melanoma-s-i31-SLNB-Result-Outperforms-Staging-Criteria-in-Identifying-Patients-with-Cutaneous-M.html">Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma&#39;s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB</a>
    </div>

      <div class="me-0 me-md-5">
        Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma&#39;s integrated SLNB test result.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Castle-Biosciences-Inc-US14843C1053/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>